Vertex says telaprevir may cut down HCV treatment time

08/11/2010 | Google

Some hepatitis C patients who took drug candidate telaprevir were able to finish treatment sooner than with standard therapy, according to Vertex Pharmaceuticals. The company said patients in the clinical trial who responded quickly to telaprevir had better results after 24 weeks of therapy compared with 48 weeks.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX